Navigation Links
Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
Date:4/18/2013

za. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

CONTACTS:
Investors: Bernie Hertel , Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson , Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of
'/>"/>

SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage ... positive, statistically significant top-line results from its ANCHOR trial for ... met its primary and secondary efficacy endpoints for both the ... The purpose of the ANCHOR trial was to demonstrate that ...
... and SYDNEY, April 15, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory ... advanced heart failure, today announced the presentation of ... transplantation (BTT) study, ADVANCE, showing 180-day survival, using ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... ... ... Noni International (TNI) announced that Tahitian Noni® Bioactive Beverages™ contain iridoids —a bioactive ... for over 50 years and now 12 unique iridoids have been identified in the ...
... ... and after pictures and a directory for patients looking to find a plastic surgeon ... laser skin care. , ... (PRWEB) March 11, 2010 -- MyCosmeticProcedures.com is a new website focused ...
... , ... Technology Leadership with Largest Number of Highly Automated QT(sm) and QT Beat-to-Beat(sm) Studies ... Rochester, N.Y. (PRWEB) ... services and QT analysis, announced today that a top 10 pharmaceutical company has awarded ...
... LocalITCompanies.com ... be expanding nationwide. Local IT Companies connects businesses with up to three pre-screened IT service ... ... owners are entrenched in their own day to day business building operations and the thought ...
... Delphi ... Hospital in Hayward, California , ... Morrisville, NC (PRWEB) March 11, 2010 -- Delphi Healthcare Partners, Inc. ( ... provide a comprehensive OB/Gyn solution. With help from Delphi, St. Rose is in ...
... number of younger minority adults receiving medical care in settings ... the healthcare safety net). Poor, minority adults with moderate to ... to progress to kidney failure than non-Hispanic whites. These are ... Clinical Journal of the American Society of Nephrology (CJASN). ...
Cached Medicine News:Health News:12 Unique Iridoids Have Been Found in Noni Fruit 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 3Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 4Health News:Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Delphi Healthcare Partners Announces New Obstetrics/Gynecology Programs in Hayward, California 2Health News:Study: Kidney disease a big risk for younger, low-income minorities 2
West 2 periosteal elevators....
Semb periosteal elevators....
Williger periosteal elevators....
Lambotte periosteal elevators....
Medicine Products: